Blade Clinical Trials

Today, we are advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases.

Find Clinical Trials Near Me

Program	Indication	Study Phase	Status	Trial number
BLD-0409	Healthy Volunteer Safety Testing	Phase 1	Complete	NCT04146805
BLD-0409-102	Relative Bioavailability	Phase 1b	In Process	NCT04814472
BLD-0409-103	Drug-Drug Interaction	Phase 1b	In Process	NCT04814498
BLD-0409-104	Drug-Drug Interaction with IPF Standard of Care Therapies	Phase 1b	Planned
BLD-0409-203	Idiopathic Pulmonary Fibrosis	Phase 2	Planned